Greffes de cellules souches hématopoïétiques à partir d’un donneur haploidentique : recommandations de la SFGM-TC (deuxième partie)

Pathologie-biologie Pub Date : 2014-08-01 DOI:10.1016/j.patbio.2014.05.002

S. Nguyen , D. Blaise , J.-O. Bay , P. Chevallier , N. Contentin , N. Dhédin , R. Duléry , J.-F. Eliaou , M.-T. Rubio , F. Suarez , C.-E. Bulabois , J. Cornillon , A. Huynh , L. Magro , M. Michallet , C. Paillard , P. Turlure , I. Yakoub-Agha

{"title":"Greffes de cellules souches hématopoïétiques à partir d’un donneur haploidentique : recommandations de la SFGM-TC (deuxième partie)","authors":"S. Nguyen , D. Blaise , J.-O. Bay , P. Chevallier , N. Contentin , N. Dhédin , R. Duléry , J.-F. Eliaou , M.-T. Rubio , F. Suarez , C.-E. Bulabois , J. Cornillon , A. Huynh , L. Magro , M. Michallet , C. Paillard , P. Turlure , I. Yakoub-Agha","doi":"10.1016/j.patbio.2014.05.002","DOIUrl":null,"url":null,"abstract":"<div><p>Haploidentical allogeneic stem cell transplantation (CST) has globally taken off in the past decade. It appears to be a valid alternative to other sources of stem cells; however, further research is necessary to validate the use of this approach in standard patient care. In the attempt to harmonize clinical practices between different French transplantation centers, the French Society of Bone Marrow Transplantation and Cell Therapies (SFGM-TC) set up its fourth annual series of workshops which brought together practitioners from all of its member centers. These workshops took place in September 2013 in Lille. This is part two of the recommendations regarding allogeneic stem cell transplantation from an HLA-haploidentical related donor.</p></div>","PeriodicalId":19743,"journal":{"name":"Pathologie-biologie","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2014-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.patbio.2014.05.002","citationCount":"11","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pathologie-biologie","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0369811414000625","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 11

Abstract

Haploidentical allogeneic stem cell transplantation (CST) has globally taken off in the past decade. It appears to be a valid alternative to other sources of stem cells; however, further research is necessary to validate the use of this approach in standard patient care. In the attempt to harmonize clinical practices between different French transplantation centers, the French Society of Bone Marrow Transplantation and Cell Therapies (SFGM-TC) set up its fourth annual series of workshops which brought together practitioners from all of its member centers. These workshops took place in September 2013 in Lille. This is part two of the recommendations regarding allogeneic stem cell transplantation from an HLA-haploidentical related donor.

查看原文本刊更多论文

单倍相同供体造血干细胞移植:SFGM-TC的建议(第二部分)

单倍体同种异体干细胞移植(CST)是近十年来在全球范围内兴起的一项研究。它似乎是其他干细胞来源的有效替代品;然而，需要进一步的研究来验证这种方法在标准患者护理中的应用。为了协调法国不同移植中心的临床实践，法国骨髓移植和细胞治疗协会(SFGM-TC)举办了第四次年度系列研讨会，汇集了所有成员中心的从业人员。这些研讨会于2013年9月在里尔举行。这是关于同种异体干细胞移植的建议的第二部分，来自hla -单倍体相同的相关供体。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pathologie-biologie 医学-病理学

自引率

0.00%

发文量

审稿时长

6-12 weeks